Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15356908 | 0.88 | S1PR2 (0.40) | USP2ALOX15MEN1KMT2AKDM4E | |
| SCHEMBL13979814 | 0.85 | — | — | |
| SCHEMBL3427413 | 0.81 | MAPT (0.39) | USP2ALOX15MEN1KMT2AKDM4E | |
| SCHEMBL15356911 | 0.81 | S1PR2 (0.55) | USP2ALOX15S1PR2S1PR1S1PR3 | |
| SCHEMBL15356915 | 0.81 | FDPS (0.48) | USP2ALOX15MEN1KMT2AMMP2 | |
| SCHEMBL4353438 | 0.80 | — | — | |
| SCHEMBL15356917 | 0.79 | S1PR2 (0.35) | USP2ALOX15MEN1KMT2AS1PR2 | |
| SCHEMBL15722838 | 0.79 | S1PR2 (0.39) | USP2ALOX15MEN1KMT2AMMP2 | |
| SCHEMBL126893 | 0.79 | MVD (0.46) | USP2ALOX15MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL11288828 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11668169-B2 | Reactive surfactant flooding at neutral pH | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-06-06 | — | — | US | claimed |
| WO-2023059342-A1 | NANOPARTICLE WEDGE EFFECT TO INDUCE WATER WETTABILITY | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-04-13 | — | — | WO | claimed |
| US-20230115715-A1 | NANOPARTICLE WEDGE EFFECT TO INDUCE WATER WETTABILITY | HALLIBURTON ENERGY SERVICES, INC. | 2023-04-13 | — | — | US | claimed |
| US-20230065437-A1 | ACIDIZING OF SUBTERRANEAN FORMATIONS WITH PLACEMENT OF SCALE INHIBITOR | HALLIBURTON ENERGY SERVICES, INC. | 2023-03-02 | — | — | US | claimed |
| WO-2023022726-A1 | ACIDIZING OF SUBTERRANEAN FORMATIONS WITH PLACEMENT OF SCALE INHIBITOR | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-02-23 | — | — | WO | claimed |
| US-11566169-B2 | Rapid reversal of wettability of subterranean formations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-01-31 | — | — | US | claimed |
| WO-2022115283-A1 | METHOD FOR IMPROVED OIL RECOVERY IN SUBTERRANEAN FORMATIONS WITH CIRCUMNEUTRAL PH FLOOD | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115284-A1 | REACTIVE SURFACTANT FLOODING AT NEUTRAL PH | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220162496-A1 | FLUIDS FOR SINGLE AND MULTI PAD DELIVERY | HALLIBURTON ENERGY SERVICES, INC. | 2022-05-26 | — | — | US | claimed |
| US-20220162498-A1 | METHOD FOR IMPROVED OIL RECOVERY IN SUBTERRANEAN FORMATIONS WITH CIRCUMNEUTRAL pH FLOOD | HALLIBURTON ENERGY SERVICES, INC. | 2022-05-26 | — | — | US | claimed |
| WO-2020101649-A1 | RAPID REVERSAL OF WETTABILITY OF SUBTERRANEAN FORMATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2020-05-22 | — | — | WO | claimed |
| US-20200157413-A1 | METHOD AND PROCESS OF USE OF BINARY COMPOSITIONS FOR ACIDIZING SUBTERRANEAN FORMATIONS | HALLIBURTON ENERGY SERVICES, INC. | 2020-05-21 | — | — | US | claimed |
| US-20100160211-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20040063916-A1 | Bactericides; antibiotics | CUMBERLAND PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| JP-2004501161-A | — | — | 2004-01-15 | — | — | JP | claimed |
| US-20030207797-A1 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | CUMBERLAND PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | claimed |
| US-6635618-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. | 2003-10-21 | — | — | US | claimed |
| EP-1292612-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | Advanced Medicine, Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | claimed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160211-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | USP2 4248/4885ALOX15 3903/4885MEN1 3943/4885 |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | GLS, PIGS, PAG1 | USP2 4546/4885ALOX15 3402/4885MEN1 2927/4885 |
| US-20030207797-A1 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | PAG1, PTMS, B3GAT3 | USP2 4131/4885ALOX15 3031/4885MEN1 2472/4885 |
| US-20040063916-A1 | Bactericides; antibiotics | PGLS, PAG1, BPGM | USP2 3544/4885ALOX15 3690/4885MEN1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.